Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab.

Nishino M, Cryer SK, Okajima Y, Sholl LM, Hatabu H, Rabin MS, Jackman DM, Johnson BE.

Cancer Imaging. 2012 Jun 29;12:225-35. doi: 10.1102/1470-7330.2012.0027.

2.

Molecularly targeted therapy using bevacizumab for non-small cell lung cancer: a pilot study for the new CT response criteria.

Lee HY, Lee KS, Hwang HS, Lee JW, Ahn MJ, Park K, Kim TS, Yi CA, Chung MJ.

Korean J Radiol. 2010 Nov-Dec;11(6):618-26. doi: 10.3348/kjr.2010.11.6.618. Epub 2010 Oct 29.

3.

Tumor cavitation during therapy with antiangiogenesis agents in patients with lung cancer.

Marom EM, Martinez CH, Truong MT, Lei X, Sabloff BS, Munden RF, Gladish GW, Herbst RS, Morice RC, Stewart DJ, Jimenez CA, Blumenschein GR Jr, Onn A.

J Thorac Oncol. 2008 Apr;3(4):351-7. doi: 10.1097/JTO.0b013e318168c7e9.

4.

Imaging Tumor Response and Tumoral Heterogeneity in Non-Small Cell Lung Cancer Treated With Antiangiogenic Therapy: Comparison of the Prognostic Ability of RECIST 1.1, an Alternate Method (Crabb), and Image Heterogeneity Analysis.

Yip C, Tacelli N, Remy-Jardin M, Scherpereel A, Cortot A, Lafitte JJ, Wallyn F, Remy J, Bassett P, Siddique M, Cook GJ, Landau DB, Goh V.

J Thorac Imaging. 2015 Sep;30(5):300-7. doi: 10.1097/RTI.0000000000000164.

PMID:
26164165
5.

Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.

Le Moulec S, Hadoux J, Gontier E, Chargari C, Helissey C, Lamand V, Tanz R, Farace F, Vedrine L, Bonardel G, Soria JC, Besse B.

Bull Cancer. 2013 Dec;100(12):30-7. doi: 10.1684/bdc.2013.1864.

PMID:
24316967
6.

Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer.

Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA, Powers J, Seymour L, Laurie SA.

J Clin Oncol. 2009 Jan 20;27(3):404-10. doi: 10.1200/JCO.2008.16.2545. Epub 2008 Dec 1.

PMID:
19047292
7.

Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab.

Sandler AB, Schiller JH, Gray R, Dimery I, Brahmer J, Samant M, Wang LI, Johnson DH.

J Clin Oncol. 2009 Mar 20;27(9):1405-12. doi: 10.1200/JCO.2008.16.2412. Epub 2009 Feb 17. Erratum in: J Clin Oncol. 2009 Jul 10;27(20):3410.

8.

Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study.

Lynch TJ Jr, Spigel DR, Brahmer J, Fischbach N, Garst J, Jahanzeb M, Kumar P, Vidaver RM, Wozniak AJ, Fish S, Flick ED, Leon L, Hazard SJ, Kosty MP; ARIES Study Investigators..

J Thorac Oncol. 2014 Sep;9(9):1332-9. doi: 10.1097/JTO.0000000000000257.

9.

[Analysis of cavitation of advanced NSCLC treated by rh-endostatin combined with NP chemotherapy].

Huang C, Wang LC, Xiao JY, Ye ZX, Liu ZJ, Xu WJ, Cheng X, Wang J, Li K.

Zhonghua Zhong Liu Za Zhi. 2008 Sep;30(9):712-5. Chinese.

PMID:
19173919
10.

Dual-energy CT in patients treated with anti-angiogenic agents for non-small cell lung cancer: new method of monitoring tumor response?

Kim YN, Lee HY, Lee KS, Seo JB, Chung MJ, Ahn MJ, Park K, Kim TS, Yi CA.

Korean J Radiol. 2012 Nov-Dec;13(6):702-10. doi: 10.3348/kjr.2012.13.6.702. Epub 2012 Oct 12.

11.

Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer.

De Braganca KC, Janjigian YY, Azzoli CG, Kris MG, Pietanza MC, Nolan CP, Omuro AM, Holodny AI, Lassman AB.

J Neurooncol. 2010 Dec;100(3):443-7. doi: 10.1007/s11060-010-0200-2. Epub 2010 May 4.

12.

Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.

Cabebe E, Wakelee H.

Curr Treat Options Oncol. 2007 Feb;8(1):15-27. Review.

PMID:
17634832
13.

Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort study.

Takagi Y, Toriihara A, Nakahara Y, Yomota M, Okuma Y, Hosomi Y, Shibuya M, Okamura T.

PLoS One. 2013;8(3):e59700. doi: 10.1371/journal.pone.0059700. Epub 2013 Mar 26.

14.

Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers.

Chaft JE, Rusch V, Ginsberg MS, Paik PK, Finley DJ, Kris MG, Price KA, Azzoli CG, Fury MG, Riely GJ, Krug LM, Downey RJ, Bains MS, Sima CS, Rizk N, Travis WD, Rizvi NA.

J Thorac Oncol. 2013 Aug;8(8):1084-90. doi: 10.1097/JTO.0b013e31829923ec.

15.

MO19390 (SAiL): bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC.

Dansin E, Cinieri S, Garrido P, Griesinger F, Isla D, Koehler M, Kohlhaeufl M.

Lung Cancer. 2012 Jun;76(3):373-9. doi: 10.1016/j.lungcan.2011.11.020. Epub 2012 Jan 10.

PMID:
22236866
16.

[Paclitaxel-bevacizumab is a possible alternative as salvage chemotherapy in advanced non-small cell bronchial carcinoma].

Zarza V, Couraud S, Bosc C, Toffart AC, Moro-Sibilot D, Souquet PJ.

Rev Mal Respir. 2014 Sep;31(7):601-7. doi: 10.1016/j.rmr.2013.05.011. Epub 2013 Nov 9. French.

PMID:
25239581
17.

Tumor cavitation in stage I non-small cell lung cancer: epidermal growth factor receptor expression and prediction of poor outcome.

Onn A, Choe DH, Herbst RS, Correa AM, Munden RF, Truong MT, Vaporciyan AA, Isobe T, Gilcrease MZ, Marom EM.

Radiology. 2005 Oct;237(1):342-7.

PMID:
16183941
18.

A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).

Raez LE, Santos ES, Webb RT, Wade J, Brito RA, Karr M, Kennah A, Childs BH.

Cancer Chemother Pharmacol. 2013 Nov;72(5):1103-10. doi: 10.1007/s00280-013-2301-z. Epub 2013 Sep 22.

PMID:
24057043
19.

Bevacizumab in lung cancer: lackluster performance and unjustified expense?

Dasanu CA.

J Oncol Pharm Pract. 2012 Sep;18(3):381-2. doi: 10.1177/1078155212453607. Epub 2012 Jul 9.

PMID:
22777997
20.

Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer.

Klamerus JF, Brahmer JR.

Clin Lung Cancer. 2008 Mar;9 Suppl 2:S51-6. doi: 10.3816/CLC.2008.s.008. Review.

PMID:
21884999

Supplemental Content

Support Center